Evolocumab Increases Apolipoprotein A1 Remnant Ratio After 12 Weeks
This post hoc analysis is the first to suggest that evolocumab increases the apolipoprotein A1 remnant ratio following 12 weeks of treatment.
Virginia A. Schad, PharmD, RPh
Contributing Writer https://www.endocrinologyadvisor.com
Virginia A. Schad, PharmD, RPh, is a contributing medical author for the Haymarket Medical Network, part of the Medical Communications Group of Haymarket Media. She earned her Doctor of Pharmacy degree at the University of Pittsburgh in Pittsburgh, Pennsylvania, in 1999. For the past 20 years, Dr Schad has worked in medical communications developing numerous presentations, as well as slide libraries and kits, and editing journal articles and supplements, clinical study reports, product monographs, and program abstracts. She has also organized and implemented speaker training meetings, consultants’ meetings, advisory board meetings, roundtable meetings, and CME symposia. While Dr Schad has worked in many therapeutic areas, her areas of focus have been in endocrinology, infectious diseases, pulmonology, neurology, and cardiology.
